
Switching frail AF patients from VKA to NOAC increases bleeding risk without reducing thromboembolic complications or mortality.


coremsg

Frail patients with atrial fibrillation who were switched to a newer NOAC agent had more bleeding than those left on older vitamin K antagonists, without any benefit in terms of thromboembolic events.

VKA Therapy Beats Switch to NOAC in Frail AF Patients

switching-from-vka-to-noac-in-frail-af-patients-increases-bleeding-risk


Switching from VKA to NOAC in Frail AF Patients Increases Bleeding Risk
